** Shares of Dimerix DXB.AX rise as much as 31% to A$0.465, their biggest intraday pct gain since mid-October 2023
** Biopharmaceutical firm enters exclusive agreement with Osaka-based FUSO Pharmaceutical Industries 4538.T to develop and commercialise kidney disease drug candidate DMX-200 in Japan
** ASX-listed firm says it will receive 300 million Yen ($1.90 million) within 40 days of signing the deal, with a potential additional 400 million Yen ($2.54 million) expected upon the start of the first clinical trial site, anticipated in Q1 2025
** Adds, the deal includes potential development and commercialisation milestones of up to 9.8 billion Yen ($62.17 million), in addition to royalties ranging from 15% to 20% on net sales of the drug, if successfully commercialised
** Stock hits its highest level since Oct. 21, 2024
** Over 4.7 mln shares change hands, ~3.6x the 30-day avg
** Dimerix gained 65.9% last year vs its Japanese peer's gains of 34.4%
($1 = 157.7800 yen)
(Reporting by Kumar Tanishk in Bengaluru)
((Tanishk.Kumar@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.